Carbohydrate Tumor Marker: Basis for a Simple Test for Colorectal Cancer

1994 ◽  
pp. 85-99 ◽  
Author(s):  
Abulkalam M. Shamsuddin ◽  
Kosaku Sakamoto
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Simple Test

Paired tumor marker of soluble E-selectin and its ligand sialyl Lewis A in colorectal cancer

2001 ◽  
Vol 36 (12) ◽  
pp. 823-829 ◽  
Author(s):  
Katsuki Ito ◽  
ChunLin Ye ◽  
Kenji Hibi ◽  
Chikako Mitsuoka ◽  
Reiji Kannagi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Sialyl Lewis ◽  
Sialyl Lewis A ◽  
Soluble E Selectin ◽  
Lewis A

Serum p53 Antibody as Tumor Marker for Follow-Up of Colorectal Cancer After Curative Resection

2009 ◽  
Vol 16 (9) ◽  
pp. 2516-2523 ◽  
Author(s):  
Reiping Tang ◽  
Chien Yuh Yeh ◽  
Jeng-Yi Wang ◽  
Chung Rong Changchien ◽  
Jinn-Shiun Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Curative Resection ◽  
Serum P53 Antibody ◽  
Serum P53 ◽  
P53 Antibody

scholarly journals CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression

2020 ◽  
Vol 21 (6) ◽  
pp. 2040 ◽  
Author(s):  
Sara Pączek ◽  
Marta Łukaszewicz-Zając ◽  
Mariusz Gryko ◽  
Piotr Mroczko ◽  
Agnieszka Kulczyńska-Przybik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Cancer Progression ◽  
Characteristic Curve ◽  
Distant Metastases ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Predictive Values ◽  
Potential Biomarker ◽  
Tumor Stages

Introduction. Since colorectal cancer (CRC) is the second most commonly diagnosed malignancy in Europe and third worldwide, novel biomarkers for diagnosing the disease are critically needed. Objectives. According to our knowledge, the present study is the first to evaluate the clinical usefulness of serum CXCL-8 (C-X-C motif chemokine 8) in the diagnosis and progression of CRC compared to classical tumor marker CEA (carcinoembryonic antigen) and marker of inflammation CRP (C-reactive protein). Patients and Methods. The study included 59 CRC patients and 46 healthy volunteers. Serum levels of selected proteins were measured using ELISA (enzyme-linked immunosorbent assay), CMIA (chemiluminescent microparticle immunoassay), and immunoturbidimetric methods. Results. Serum concentrations of CXCL-8, similarly to those of the classical tumor marker CEA and inflammatory state marker CRP, were significantly higher in CRC patients than in healthy controls. There were statistically significant differences in CXCL-8 concentrations between tumor stages, as established by the Kruskal–Wallis test and confirmed by the post hoc Dwass–Steele–Critchlow–Fligner test. CXCL-8 levels were also significantly elevated in CRC patients with distant metastases compared to patients in the subgroup without metastases. Diagnostic sensitivity, predictive values for negative results (NPV), and AUC (area under the Receiver Operating Characteristic Curve—ROC curve) of CXCL-8 were higher than those of CEA, while diagnostic specificity and predictive values for positive results (PPV) of CXCL-8 were higher than those of CRP. Conclusions. Our findings indicate greater utility of CXCL-8 in comparison to the classical tumor marker CEA in the diagnosis of CRC. Moreover, serum CXCL-8 might be a potential biomarker of colorectal cancer progression.

Abstract 3464: Low concordance with CEA tumor marker monitoring in colorectal cancer survivors

2016 ◽  
Author(s):  
Guadalupe Palos ◽  
Katherine R. Gilmore ◽  
Patricia Chapman ◽  
Paula Lewis-Patterson ◽  
Weiqi Bi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Survivors ◽  
Tumor Marker ◽  
Colorectal Cancer Survivors

scholarly journals Circular noncoding RNA circMBOAT2 is a novel tumor marker and regulates proliferation/migration by sponging miR-519d-3p in colorectal cancer

2020 ◽  
Vol 11 (8) ◽  
Author(s):  
Xiaolong Tang ◽  
Guorui Sun ◽  
Qingsi He ◽  
Chao Wang ◽  
Jingbo Shi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Noncoding Rna

scholarly journals Significance of transforming growth factor ?1 as a new tumor marker for colorectal cancer

2002 ◽  
Vol 97 (4) ◽  
pp. 508-511 ◽  
Author(s):  
Shin Narai ◽  
Masahiko Watanabe ◽  
Hirotoshi Hasegawa ◽  
Hideki Nishibori ◽  
Takashi Endo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Tumor Marker ◽  
Transforming Growth Factor

Do insulin-like growth factor associated proteins qualify as a tumor marker?

2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 18-18
Author(s):  
Christiane Matuschek ◽  
Matthias Peiper ◽  
Wilfried Budach ◽  
Peter Arne Gerber ◽  
Hans Bojar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Tumor Marker ◽  
Head And Neck ◽  
Sensitivity And Specificity ◽  
Metastatic Disease ◽  
Serum Levels ◽  
Insulin Like Growth Factor ◽  
Neck Tumors ◽  
Igf System

18 Background: Insulin-like growth factor (IGF)-1, -2 and insulin-like growth factor binding proteins (IGFBP) are involved in the proliferation and differentiation of cells. It has never been evaluated if the IGF-system can serve as a tumor marker in neoplasms. Methods: In our prospective study, 163 patients with colorectal cancer (22), prostate cancer (21), glioblastoma (12), head and neck tumors (17), lymphomas (20), lung cancer (34), and other entities (37) were analysed for their IGF and IGFBP serum levels at the beginning and the end of radiotherapy and compared with 13 healthy people. Subgroups of patients with local tumor disease versus metastatic disease, primary and recurrent therapy and curative versus palliative therapy were compared. Results: The serum levels of IGF-2 were significantly elevated in patients with prostate and colorectal cancer. However, sensitivity and specificity were only 70%. IGFBP-2 serum levels were elevated in patients with head and neck tumors. Again, sensitivity and specificity were only 73%. A difference between local disease and metastatic disease could not be found. A difference between IGF serum levels before and after radiotherapy could not be detected. Conclusions: The IGF-system cannot serve as a new tumor marker. The detected differences are very small and sensitivity and specificity are too low. IGF measurement is not useful for the evaluation of the success of radiotherapy in malignancies.

Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 654-654
Author(s):  
Toshiyasu Watanabe ◽  
Eiji Shinozaki ◽  
Sho Kijima ◽  
Yoshihito Ohhara ◽  
Yasutoshi Kuboki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Clinical Benefit ◽  
Chemotherapy Response ◽  
Chimeric Mouse ◽  
Serum Tumor Marker ◽  
Wild Type ◽  
Tumor Marker Level ◽  
Marker Level

654 Background: Panitumumab and cetuximab can be used in metastatic colorectal cancer (mCRC) and these drugs are IgG2 fully human and IgG1 chimeric (mouse/human) monoclonal antibody against the epidermal growth hactor receptor (EGFR) respectively. The efficacy of panitumumab as a salvage chemotherapy after cetuximab-based chemotherapy failure is not clarified. Methods: This study aimed to evaluate the panitumumab efficacy to KRAS wild-type mCRC patients who failed cetuximab-based chemotherapy. Response, progression-free survival (PFS) and serum tumor marker level (CEA and CA19-9), were assesed. We studied response by days from last cetuximab-based chemotherapy to panitumumab induction (C-P days). Results: 22 patients (11 men, 11 women, median age 54 years m4 0-78 n) were enrolled. All of thease patients were cetuximab-based chemotherapy refractory KRAS wild-type mCRC. After progression, they received panitumumab monotherapy (6 mg/kg every 2 weeks).The best response was SD 10/22 (45.5%), PD 11/22 (50%) and NE 1/22 (4.5%). Overall median PFS was 90 days (13 to 182). The patients C-P days less than 30 days were 15 patients(5:SD, 10:PD). The patients more than 79 days were 7 patient(5:SD, 1:PD, 1:NE). Serum tumor marker level was decreased more than 50% patients. Conclusions: This study suggested that it might be limited as possibility of clinical benefit with panitumumab administration after cetuximab failure.

Identification of HSP27 as a potential tumor marker for colorectal cancer by the two-dimensional polyacrylamide gel electrophoresis

2009 ◽  
Vol 37 (7) ◽  
pp. 3207-3216 ◽  
Author(s):  
Weijie Liu ◽  
Yanlei Ma ◽  
Long Huang ◽  
Jiayuan Peng ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Marker ◽  
Gel Electrophoresis ◽  
Polyacrylamide Gel Electrophoresis ◽  
Polyacrylamide Gel ◽  
Two Dimensional
Sign in / Sign up

Export Citation Format

Share Document